BiotechTube

Povorcitinib + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NonSegmental Vitiligo

Conditions

NonSegmental Vitiligo

Trial Timeline

Nov 29, 2023 → Feb 24, 2027

NCT ID
NCT06113445

About Povorcitinib + Placebo

Povorcitinib + Placebo is a phase 3 stage product being developed by Incyte for NonSegmental Vitiligo. The current trial status is active. This product is registered under clinical trial identifier NCT06113445. Target conditions include NonSegmental Vitiligo.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (7)

NCT IDPhaseStatus
NCT06516952Phase 3Recruiting
NCT06516965Phase 3Recruiting
NCT06113445Phase 3Active
NCT06113471Phase 3Active
NCT05936567Phase 2Completed
NCT05620836Phase 3Completed
NCT05620823Phase 3Completed

Competing Products

7 competing products in NonSegmental Vitiligo

See all competitors
ProductCompanyStageHype Score
Ritlecitinib + Ritlecitinib + PlaceboPfizerPhase 3
76
Ritlecitinib + PlaceboPfizerPhase 3
76
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Ruxolitinib CreamIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74